RxDoctor Payments Data

Alberto Caintic, MD

Nephrology · Tampa, FLNPI 1679688006

Payments from drug & device makers

$882in general payments, 2019–2025

Across 20 payments — averaging $44.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$226
  • Bayer$209
  • Mallinckrodt Hospital Products Inc.$160
  • Amgen$97
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$58
  • Emergent Biosolutions Inc.$57
  • plus $74 from 2 others

What the payments were for

  • Food & beverage$882100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$882 in reported general payments places this provider in the 35th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$26,984
Medicare patients
39
Services billed
265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol39$37,336
Tamsulosin Hcl26$486
Calcitriol29$316
Atorvastatin Calcium30$309
Allopurinol25$223
Folic Acid16$200
Furosemide24$193
Levothyroxine Sodium16$183
Hydralazine Hcl17$161
Losartan Potassium12$141
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide14$139
Amlodipine Besylate22$133
Spironolactone16$88
Carvedilol16$65
Hydrochlorothiazide14$63

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$226$37,33639 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 756 nephrology providers in Florida.

Other nephrology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →